Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer

NCT06759090 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Pancreatic Carcinoma

Interventions

DRUG: Metronomic capecitabine
DRUG: Camrelizumab
DRUG: Apatinib Mesylate Tablets

Sponsor

Zhejiang University